Encukalner
Focal Epilepsy
Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Xenon Pharmaceuticals Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05716100CT.gov A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | — | Recruiting | — | — | — |
NCT05718817CT.gov An Open-label Study of XEN1101 in Epilepsy | — | Enrolling By Invitation | — | — | — |
NCT05614063CT.gov A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | — | Completed | — | — | — |
NCT03796962CT.gov A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Focal Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Encukalner (this asset) | Xenon Pharmaceuticals Inc. | P3 | BB · 67 |
| Pregabalin | Yung Shin Pharm. Ind. Co., Ltd. | P4 | A |
| Eslicarbazepine Acetate | Sumitomo Pharma America, Inc. | P4 | A |
| Oxcarbazepine | Mario Negri Institute for Pharmacological Research | P4 | A |
| Topiramate | Mario Negri Institute for Pharmacological Research | P4 | A |
| Lacosamide | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | P4 | A |
| Lamotrigine | Dhaka Medical College | P4 | BBB |
| Cenobamate | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Gabapentin | Mario Negri Institute for Pharmacological Research | P4 | BBB |
+42 more in the Focal Epilepsy cohort
Other indications for Encukalner
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy With Generalized Tonic-Clonic Seizures | — | P3 | B · 60 |
| Bipolar Depression | — | P3 | B · 57 |
| Bipolar I Disorder | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Encukalner in Focal Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/encukalner-focal-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →